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Background: In addition to smoking, genetic predisposition is believed to play a major role in the pathogenesis of
chronic obstructive pulmonary disease (COPD). Genetic association studies of new candidate genes in COPD may
lead to improved understanding of the pathogenesis of the disease.
Methods: Two proposed casual single nucleotide polymorphisms (SNP) (rs1051740, rs2234922) in microsomal
epoxide hydrolase (EPHX1) and three SNPs (rs1801282, rs1800571, rs3856806) in peroxisome proliferator-activated
receptor gamma (PPARG), a new candidate gene, were genotyped in a case-control study (272 COPD patients and
301 controls subjects) in Hungary. Allele frequencies and genotype distributions were compared between the two
cohorts and trend test was also used to evaluate association between SNPs and COPD. To estimate the strength of
association, odds ratios (OR) (with 95% CI) were calculated and potential confounding variables were tested in
logistic regression analysis. Association between haplotypes and COPD outcome was also assessed.
Results: The distribution of imputed EPHX1 phenotypes was significantly different between the COPD and the
control group (P = 0.041), OR for the slow activity phenotype was 1.639 (95% CI = 1.08- 2.49; P = 0.021) in our
study. In logistic regression analysis adjusted for both variants, also age and pack-year, the rare allele of His447His
of PPARG showed significant association with COPD outcome (OR = 1.853, 95% CI = 1.09-3.14, P = 0.0218). In
haplotype analysis the GC haplotype of PPARG (OR = 0.512, 95% CI = 0.27-0.96, P = 0.035) conferred reduced risk
for COPD.
Conclusions: The “slow” activity-associated genotypes of EPHX1 were associated with increased risk of COPD. The
minor His447His allele of PPARG significantly increased; and the haplotype containing the minor Pro12Ala and the
major His447His polymorphisms of PPARG decreased the risk of COPD.
Background
Chronic obstructive pulmonary disease (COPD) is an
increasing and serious public health problem represent-
ing the fourth leading cause of death globally. COPD is
a complex human disease, associated with persistent air-
way inflammation, protease-anti-protease imbalance,
oxidative stress, chronic obstructive bronchitis and
emphysema, resulting in progressive airflow limitation
that is not substantially reversed by bronchodilators.
Importantly, it is a smoking-related disorder and cigar-
ette smoking is the major environmental risk factor for
d e v e l o p m e n to fC O P D .H o w e v e r ,t h ef a c tt h a to n l ya
subset of smokers (15-20%) develops clinically signifi-
cant symptoms suggests that genetic predisposition also
plays role in the development of COPD [1,2].
Previous genetic association and genome-wide linkage
studies have identified several candidate genes that
might be involved in the pathogenesis of COPD [3-7].
In our case-control study, five putative causal single
nucleotide polymorphisms (SNPs) in two genes -
* Correspondence: penyige@med.unideb.hu; nagyl@med.unideb.hu
† Contributed equally
1Department of Human Genetics, University of Debrecen, Debrecen,
Hungary
2Department of Biochemistry and Molecular Biology, Research Center for
Molecular Medicine, University of Debrecen, Debrecen, Hungary
Full list of author information is available at the end of the article
Penyige et al. BMC Medical Genetics 2010, 11:152
http://www.biomedcentral.com/1471-2350/11/152
© 2010 Penyige et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.microsomal epoxide hydrolase (EPHX1) and peroxisome
proliferator-activated receptor gamma (PPARG)-w e r e
chosen to analyze their association with COPD.
PPARG is a member of nuclear hormone receptors,
implicated in adipocyte differentiation and involved in
macrophage activation and dendritic cell biology [8]. An
anti-inflammatory role of PPARG was also reported
based on its inhibitory effect on pro-inflammatory tran-
scription factors such as NF-Ba n dA P - 1[ 9 , 1 0 ] .T h e
NCBI SNP database features more than 700 polymorph-
isms of PPARG, many of them intronic or synonymous
variant and generally lack of information regarding
population diversity.
Several studies on the polymorphisms of PPARG such
as Pro12Ala and His447His were previously performed
in relation to inflammatory diseases such as IBD, type 2
diabetes and recently it has been suggested that PPARG
polymorphisms were associated with the risk of asthma
[11]. Since PPARG m i g h tb ei n v o l v e di nt h er e g u l a t i o n
of pro-inflammatory signaling pathways and it is gener-
ally accepted that COPD is associated with an abnormal
inflammatory response, genetic polymorphisms in
PPARG could be implicated in the susceptibility to
COPD risk [12]. That may provide a theoretical basis
for the study of this new candidate gene in COPD
development. Consequently, we examined the associa-
tion between three SNP polymorphisms of PPARG gene
and COPD.
EPHX1 is an enzyme associated with the metabolism
and detoxification of xenobiotic chemicals; it plays an
important role in the general oxidative defense of lung.
Several polymorphisms are known in EPHX1 including
two relatively common SNPs, the exon 3 Tyr113His
(rs1051740) and exon 4 His139Arg (rs2234922) variants.
These two variant alleles have been suggested to be
associated with altered EPHX1 enzyme activity [13].
Substitution of Tyr113 for His decreases EPHX1 activity
(slow allele), whereas substitution of His139 for Arg
increases EPHX1 activity (fast allele). It was found that
the slow metabolizing form of EPHX1 was associated
with an increased risk for COPD and evidence support-
ing this association has been replicated in several case-
control genetic association studies [7,14,15]. However,
the evidence supporting this association has not been
consistent, several genetic association studies failed to
show association between these polymorphisms and
COPD [16,17]. In this study we have chosen the
Tyr113His and His139Arg polymorphisms to validate
our Hungarian population for COPD association studies.
All together a total of five SNPs in two candidate
genes were genotyped in order to examine their asso-
ciation with COPD susceptibility by using Hungarian
cohorts, a previously uninvestigated population with




The study is a case-control genetic association study in
a Central-European Caucasian population. In our analy-
sis the cases included 272 and the control subjects
included 301 age-matched Hungarian individuals. The
recruitment and the clinical analyses of patients were
conducted at the Department of Pulmonology, Medical
and Health Science Center, University of Debrecen,
according to the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) criteria. The Research Ethics
Committee of University of Debrecen Medical and
Health Science Center approved the clinical protocol
and the study. Written informed consent was obtained
before the subjects entered the study. The investigator
explained the nature, purpose and risk of the study and
provided the subject with a copy of the information
sheet. The subjects were then given time to consider the
study’s implication before deciding to participate.
Before starting sample collection, we defined inclusion
and exclusion criteria of diseased and healthy patients.
Inclusion criteria for COPD subjects were age 40 to 65
years old. Patients must have predicted value of forced
expiratory volume at 1 second (FEV1) 50%-80% and
FEV1/FVC% <70% (stage 2 according to GOLD criteria).
Inclusion criteria for control patients were age between
40 and 65 years; normal spirometry, FEV1 ≥ 90% (pre-
dicted value) and FEV1/FVC% ≥ 80%. All patients must
be current or ex-smoker (minimum 15 pack years).
Exclusion criteria for all patients: plasma IgE level >70
U/ml, alpha1-antripsin deficiency, evidence of asthma,
atopic disease, history of lung disorders, respiratory
infection in the past 3 months, other inflammatory dis-
eases (e.g. inflammatory bowel disease, rheumatoid
arthritis, psoriasis etc.), autoimmune diseases (lupus,
sclerosis), cancer, positive plasma test for HIV, Hepatitis
B or Hepatitis C.
Genotyping
Genomic DNA was extracted from peripheral blood
using E.Z.N.A. Blood DNA Midi Kit (Peqlab Biotechno-
logie) according to the manufacturer’s protocol. Quality
of the DNA samples was checked by agarose gel-
electrophoresis and quantitated by NanoDrop1000. All
SNPs were genotyped using TaqMan genotyping assays
(Additional File 1, Table S1). Samples were measured in
duplicates and nuclease-free water was used as no-
template control. Following PCR amplification the end-
point fluorescence was read with the ABI 7900 HT
instrument and genotypes were assigned using SDS
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success rate of at least 95% was attained for each SNP.
Alveolar macrophage (AM) and peripheral blood
monocyte (MO) collection
Bronchoalveolar lavage fluid (BALF) samples were col-
lected by fiber-optic bronchoscopy from healthy and
COPD patients. AMs were separated by Percoll (Amer-
sham Biosciences) gradient centrifugation. Total cell
number was determined by counting in hemocytometer.
Differential cell count was assessed on hematoxylin-
eosin stained cytospin slides before and after the gradi-
ent separation. Over 95% AM purity was reached after
separation.
50 ml heparin treated venous blood was collected
from healthy and diseased patients. MOs were separated
by Ficoll gradient centrifugation using anti-CD14 conju-
gated microbeads (>98% MO) (VarioMACS, Miltenyi
Biotec.). 5-5 control and COPD patients were recruited
in this experiment.
TaqMan RT-QPCR
Total RNA was isolated from peripheral blood mono-
cytes, alveolar macrophages, lung tissue and adipose tis-
sue using Trizol reagent (Invitrogen). First strand cDNA
was generated from 5 ug total RNA using cDNA
Archive Kit (Applied Biosystems). For RT-QPCR reac-
tion 200 ng cDNA/sample and 2X TaqMan PCR mix
(Applied Biosystems) was used. Reactions were run in
ABI Prism HT 7900 instrument. We have designed pri-




3’TAMRA. The housekeeping gene cyclophilin A was
used as a normalizer gene: forward primer: 5’ACGGC-
GAGCCCTTGG, reverse primer: 5’ TTTCTGCTG
TCTTTGGGACCT, probe: 5’FAM-CGCGTCTCC
TTTGAGCTGTTTGCA-3’TAMRA. Relative gene
expression levels were calculated by comparative
Ct method. Statistical analysis was performed in Graph-
Pad Prism using non-parametric test (Mann-Whitney
U-test).
Immunohistochemistry
Tissues for morphology and immunostainings were
obtained from the files of the Pathology Department of
University of Debrecen and were freshly fixed in 10%
n e u t r a lf o r m a l i na n de m b e d d e di np a r a f f i nf o l l o w e db y
hematoxyline and eosine (HE) staining using standard
methods. Immunohistochemistry (IHC) for alveolar
macrophages (AM) was carried out using PPARG, CD68
and DCSign (Santa Cruz) monoclonal antibodies by
means of immunoperoxidase staining as described
earlier [19,20]. Double immunofluorescence staining was
performed as described earlier [21] using CSAII detec-
tion kit with FITC-labeled tyramine followed by an
immunofluorescent staining for DCSign with streptavi-
din-texas red fluorochrome. Nuclear counterstaining
was made with DAPI (blue fluorescence).
Statistical analysis
Differences between cases and the control group con-
cerning demographic and main clinical data were ana-
lyzed by Mann-Whitney U-test and Pearson c
2 test.
Genotype data for each SNP were tested for departures
from Hardy-Weinberg equilibrium (HWE) separately in
case and control populations using a goodness-of-fit
c
2-test or the exact test to estimate P values. HWE cal-
c u l a t i o n sw e r ed o n eb yu s i n gt h eH W Et o o lh t t p : / / i h g .
gsf.de/cgi-bin/hw/hwa1.pl. The significance of differ-
ences in genotype and allele frequencies between
patients and controls were tested by using either c
2 ana-
lyses or Fisher’s exact test where appropriate [22]. To
assess the degree of association between each of the
SNPs and COPD odds ratios with 95% confidence inter-
vals (OR, 95% CI) were calculated using logistic regres-
sion analysis; the model was adjusted for SNPs, pack-
year, age and gender. All single locus association tests
were performed using the STATA 9.0 statistical package
(except where otherwise stated).
Haplotype frequencies were estimated for control and
patient groups separately with the Full-Precise-Iteration
algorithm implemented in the SHEsis software http://
analysis.bio-x.cn/myAnalysis.php. The extent of linkage
disequilibrium between pairs of biallelic markers was
determined using both the standardized disequilibrium
and correlation coefficients (given as Lewontin’sD ’ and
r
2, respectively) and association between haplotypes and
COPD was assessed by the c
2-test or the exact test as
implemented in the program SHEesis [23,24]. Correc-
tion for multiple testing was not used in the analysis of
the association genotype and allele frequencies because:
(i) the EPHX1 polymorphisms were known to be func-
tional and (ii) the gene is considered a susceptibility
gene for COPD; and (iii) in case of the PPARG poly-
morphisms the studied individual alleles were not inde-
pendent. A posteriori estimates of study power were
assessed by means of Quanto software http://hydra.usc.
edu. We have estimated the power of our study with the
following parameters: sample size of 272 cases; control/
case ratio of 1.1; minor allele frequencies (MAF) are in
the range from 0.12 to 0.3; log-additive model; disease
prevalence of COPD 5%. Assuming these parameters
our study had ~50% power to detect a genotype relative
risk (GRR) of 1.4 for MAF = 0.12, or ~79% power to
d e t e c taG R Ro f1 . 6f o rt h es a m eM A F ;w h i l ei th a d
~76% power to detect a GRR of 1.4, and ~96% power to
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icance level.
Results
Of the 573 subjects genotyped, 61.8% of the subjects
were men. The proportion of males was higher among
cases (69.85% to 54.48%) but there is no significant dif-
ference in the mean age of controls and cases. Cases
had been exposed to more tobacco smoke as evidenced
by the difference in pack-years but the difference is not
significant, COPD patients had a much larger reduction
in lung function, typical for a clinical COPD population
(Table 1).
All genotype frequencies were consistent with Hardy-
Weinberg equilibrium for both SNPs of the EPHX1
gene, and the genotype and allele frequencies did not
differ significantly between cases and the control group
(Table 2). The assessment of the association of indivi-
dual SNPs with COPD showed that homozygosity for
the minor allele increased the risk of disease in case of
Tyr113His polymorphism ("slow” allele) (OR = 1.345;
95% CI = 0.96 - 1.91; P = 0.095) reduced it in case of
the His139Arg SNP ("fast” allele) (OR = 0.675; 95% CI =
0.27 - 1.69; P = 0.399). However, none of these SNPs
were significantly associated with COPD even after
adjusting the model for gender, age and pack-years in
logistic regression.
Frequencies for the four SNP based haplotypes were
estimated for cases and controls. Although the “slow
activity” CA (His
113-His
139)h a p l o t y p ew a sm o r ef r e -
quent among cases (24.8% versus the 20.8% in controls),
the overall distribution did not differ significantly
between the two groups (P = 0.736). Furthermore,
alleles of the two loci in EPHX1 are in complete linkage
equilibrium as shown by the pair-wise standardized dise-
quilibrium coefficient (D’ = 0.036).
Due to the presence of these coding variants, marked
variations in EPHX1 activity have been reported pre-
viously. Therefore we have assessed the association of
the predicted (rapid”, “normal”, “slow” and “very slow”)
EPHX1 phenotypes with the development of COPD
[25,26]. The distribution of predicted EPHX1 activity
was significantly different between control subjects and
COPD patients (P = 0.041). In the analysis of predicted
phenotypes the COPD group had higher proportion of
the predicted “slow” phenotype. Consequently the slow
phenotype significantly raises the risk of developing
COPD [OR = 1.639; 95% CI = 1.06-2.49; P = 0.021)] in
our case control study (Table 3).
High expression level of PPARG mRNA in the lung
has been reported previously [27,28]. We examined
PPARG expression at protein level in surgical lung tissue
samples. PPARG protein is expressed in the lung and
most of the PPARG protein derived signals co-localized
with the expression of a typical macrophage marker
CD68 and the dendritic cell marker DCSign (Figure 1).
PPARG expression was also measured at mRNA level.
mRNA expression is enriched in AM relative to total
lung tissue, however we did not find differences in
expression level between COPD and healthy individuals
(Figure 2). Thus, genetic variants, rather than the
expression of the PPARG gene could be associated with
the development of COPD.
We have genotyped three exonic SNPs (rs10801282
(Pro12Ala), rs3856806 (His447His) and rs1800571
(Pro113Gln))i nPPARG gene, but the rs1800571 locus
was left out from the analysis because it was homozy-
gous for the major C allele in all individuals. The other
two SNPs were in HWE and showed linkage disequili-
brium, the extent of LD between rs10801282 and
rs3856806 was found to be D’ = 0.673, although the pair
showed lower LD with respect to their correlation coef-
ficient (r
2 = 0.42).
The single loci allelic and genotypic analysis found
no significant association between the two coding var-
iants of PPARG and COPD. In logistic regression
applying a model adjusted for both SNPs, age and
pack-years, the rare variant of His447His polymorph-
ism was significantly associated with increased odds
for COPD (OR = 1.853, 95% CI = 1.09 - 3.14, P =
0.021). The minor Ala allele of the Pro12Ala variant
had an OR of 0.679, suggesting a protective effect,
however it did not reach significance (95% CI = 0.40 -
1.14, P = 0.145) (Table 4).
We have estimated the frequency of the possible
two-SNP haplotypes of PPARG and assessed the asso-
ciation between haplotypes and COPD development.
There was a significant difference in the frequency of
the GC haplotype involving the rare G variant of the
Pro12Ala locus between the two groups (P = 0.035).
The strength of association was also assessed, for this
haplotype (OR = 0.512; 95% CI = 0.27-0.96). This find-
ing suggests a protective effect for the GC (12Ala/
447His) haplotype of the PPARG gene for COPD out-
come (Table 5).






Male (%) 190 (69.85) 164 (54.48) 0.781
Age (±SD)* 63.87 (±8.96) 64.29 (±9.07) 0.577
Pack-Years (±SD)* 38.75 (±19.91) 34.76 (±14.71) 0.120
FEV1% predicted (±SD)* 47.17 (±13.69) 99.28 (±9.76) <0.0001
FEV1/FVC% predicted (±SD) * 57.57 (±10.12) 87.10 (±35.24) <0.001
Data presented as mean ± SD. FEV1: forced expiratory volume in one second,
FVC: forced vital capacity, *Mann-Whitney U-test was used.
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The aims of this study were to investigate association of
EPHX1 polymorphisms to COPD in a Hungarian popu-
lation and to assess possible association between SNPs
of PPARG, a new candidate gene, and COPD outcome.
In our study of individual SNPs in EPHX1 (the exon-3
Tyr113His and exon-4 His139Arg variants), the homozy-
gous minor Thr113His variant showed only a borderline
association with the COPD phenotype (P = 0.095), how-
ever the level of association was further reduced when
the model was adjusted for age, sex and pack-years.
There is complete linkage equilibrium between
Tyr113His and His139Arg SNPs and no statistical sig-
nificance was found in haplotype frequency distribution
and their association with COPD phenotype.
Since EPHX1 is involved in the detoxification of epox-
ide intermediates in tobacco smoke, the rate of conver-
sion of these highly reactive compounds could affect an
individual’s ability to cope with the toxic effect of cigar-
ette smoke [29]. We have reconstructed the frequency of
predicted EPHX1 activity in patient and control groups
[25,26]. The difference in distribution of predicted phe-
notypes was significant between the two groups. The
COPD group had a higher proportion of predicted slow
and lower proportion of predicted normal and rapid
EPHX1 activity. Interestingly the control group showed
an excess of very slow phenotypes, but its frequency was
low in both groups. In our analysis the slow activity var-
iant of EPHX1 enzyme was associated with a significantly
increased the risk for COPD. This result provides addi-
tional support to the notion that EPHX1 is likely to be
involved in COPD pathogenesis.
Previous studies about the potent anti-inflammatory
properties of the PPARG agonists suggest the use of
PPARG ligands in COPD therapy [12,30,31] and associa-
tion of PPARG gene polymorphisms with the development
of asthma has been reported [11]. These lines of evidence
prompted us to investigate PPARG gene association
existed between the presence of certain PPARG gene poly-
morphisms and COPD outcome. Using IHC staining and
RT-QPCR measurements, we have confirmed PPARG
mRNA and protein expression in lung tissues and particu-
lar in AM [32]. Although gene expression level is compar-
able in patients and healthy individuals, polymorphisms of
the gene still could be potential candidate markers of the
disease if a functionally altered PPARG has a role in the
development in COPD.
Among the three SNPs we have genotyped in PPARG
- rs1801282, rs3856806 and rs1800571 - the rs1800571
was excluded since all individuals carried an identical
homozygous genotype [33]. Our single-marker tests for
the other two coding variants yielded a significant asso-
ciation for the minor allele of His447His polymorphism
in logistic regression adjusted for both SNPs, age, sex
and pack-years (OR = 1.853; 95% CI = 1.09-3.14; P =
0.02). The His447His variant did not cause amino acid
change and it has no known function. However, several
papers pointed out that exonic synonymous SNPs can
affect mRNA splicing or stability [34,35]. Any change in
these processes could exert a significant effect on pro-
tein function, therefore there was a reason to investigate
the association of this SNP with COPD. Of course the
possibility, that the His447His SNP is tightly linked with
an unknown functional variant that determine COPD
susceptibility can not be excluded.
A modest pair-wise LD was found between rs1801282
and rs3856806. Since the use of SNP-based haplotypes






































Normal: exon3 Tyr/Tyr and exon 4 His/His or exon 3 Tyr/His and exon 4 His/
Arg; Slow: exon 3 Tyr/Tyr and exon 4 His/His; Very slow: exon 3 His/His and
exon 4 His/His; Rapid: exon 3 tyr/Tyr and exon 4 Arg/Arg or His/Arg
§c
2-test was used for the distribution of predicted phenotypes, OR: odds ratio,
CI: confidence interval
Table 2 Allele and genotype frequencies of examined EPHX1 gene polymorphisms
Gene Symbol SNP ID Allele frequency Genotype frequency
§Hardy-Weinberg Equilibrium OR (95% CI)
rs1051740 (Tyr113His) T C TT (%) TC (%) CC (%) P value
Controls 0.723 0.277 154 (53.3) 110 (38.1 25 (8.7) 0.401 1.11 (0.86-1.44)
Cases 0.701 0.299 127 (47.4) 122 (45.5) 19 (7.1) 0.154
rs2234922 (His139Arg) A G AA (%) AG (%) GG (%)
Controls 0.779 0.221 171 (60.0) 102 (35.8) 12 (4.2) 0.507 0.88 (0.66-1.18)
Cases 0.799 0.201 169 (62.8) 92 (64.2) 8 (2.9) 0.280
§c
2-test was used, OR: odds ratio, CI: confidence interval
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approach than the use of individual SNPs, a haplotype
analysis was also performed. A significant difference was
found in the frequency of GC haplotype (containing the
minor G allele of Pro12Ala and major C for His447His
variant) between the control and COPD groups and the
association of this haplotype to COPD outcome was
also determined. The GC haplotype confers a significant
lower risk for COPD, pointing to a potential functional
protective effect of this haplotype.
Interestingly the minor allele of Pro12Ala polymorph-
ism that lowers the binding affinity of PPARG protein to
Figure 1 Morphology and immunohistochemistry of COPD-associated lung lesions. A: Chronic bronchitis. B: Centriacinar emphysema.
C: Advanced active bronchitis with fibrosis and emphysema. A-C, hematoxylin-eosin staining; D: CD68-PPARG coexpression with double IHC
staining using alkaline phosphatase [red cytoplasm-CD68] and diamino-benzidine [brown nuclei-PPARG]. E: Cells with red fluorescence and green
nuclei DCSign-PPARG double fluorescence staining. Nuclear counter-staining is DAPI. Indications: b, bronchus; a, alveolar spaces; arrows, alveolar
macrophages. Original magnifications: A-D 20×; E 40×.
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showed expression in the whole lung tissue with significantly lower level (Mann-Whitney U test). However it was not expressed in peripheral
blood monocytes. Data presented normalized values of RT-QPCR measurements; Cyclophilin A was used as housekeeping gene. Grey bars
represent mean values of 5 control patients; white bars represent mean values of 5 COPD patients. ** p < 0.01.
Table 4 Allele and genotype frequencies of examined PPARG gene polymorphisms
Gene Symbol SNP ID Allele frequency Genotype frequency
§Hardy-Weinberg Equilibrium Logistic Analysis
rs1801282 (Pro12Ala) C G CC (%) CG (%) GG (%) P value OR (95% CI)
#P value
Controls 0.864 0.136 217 (75.2) 64 (22.4) 7 (2.4) 0.398 0.68 (0.40-1.14) 0.15
Cases 0.874 0.126 199 (76.2) 67 (22.3) 4 (1.5) 0.869
rs3856806 (His447His) C T CC (%) CT (%) TT (%) P value OR (95% CI)
#P value
Controls 0.882 0.118 224 (78.8) 53 (18.7) 8 (2.5) 0.09 1.85 (1.09-3.14) 0.02
Cases 0.862 0.138 199 (74.0) 65 (24.5) 5 (1.5) 0.57
§c
2-test was used, OR: odds ratio, CI: confidence interval
#Adjusted for age and pack-year
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be associated with lower body mass index, improved
insulin sensitivity, decreased risk of type 2 diabetes
[36,37] and reduced risk to develop colorectal cancer
[38]. Higher frequency of T allele of the His447His C/T
polymorphism was observed in colon cancer [39,40].
W ea r ea w a r eo ft h ef a c tt h a ts i g n i f i c a n tr e s u l t s
could prove to be false positives, and a clear limitation
of our study is the relatively low sample size. The
study has other limitations such as that population
stratification should be investigated in these kinds of
studies and we did not analyze a second cohort to
replicate our results. Possible gene-gene and gene-
environment interactions pose a difficulty for genetic
analysis of COPD association studies, too. Further stu-
dies using larger populations are needed and other var-
iants in the PPARG gene should be investigated in
order to clarify the association of PPARG and indivi-
dual susceptibility to the development of COPD.
Conclusions
In summary, our study provided support for the sug-
gested causative role of EPHX1 polymorphisms and phe-
notypes imputed from exon 3 and exon 4 genotype data
in COPD outcome in a Hungarian population.
We have carried out the first investigation of PPARG
gene polymorphisms in a case-control COPD study and
characterized the association between individual SNPs
and haplotypes in PPARG and susceptibility to COPD.
Although the GC haplotype has a modest protective
effect, it might point toward the potential importance of
common alleles with weak effect in heterogeneous dis-
eases, like COPD. The documentation of PPARG haplo-
type association with COPD identifies this important
gene as a target of further investigation for the patho-
genesis of COPD and as a potential target of therapy.
Additional material
Additional File 1: Table S1. Characteristics of tested SNP.
Characteristics, NCBI reference numbers and ABI assays code of
examined single nucleotide polymorphisms.
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